Abstract:

Objective To explore the clinical efficacy of ginseng schisandra decoction in children with lobar pneumonia （lung spleen deficiency syndrome） induced by mycoplasma pneumoniae infection and improvement of inflammatory indicators. Method 84 children with lobar pneumonia （lung spleen deficiency syndrome） caused by mycoplasma infection admitted to the First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine from January 2020 to July 2022 were selected and randomly divided into two groups with 42 cases each. The conventional group was treated according to the traditional treatment plan， while the combined group was treated with ginseng and schisandra decoction in addition to the traditional treatment plan. After 7 days， compare the differences in traditional Chinese medicine syndrome scores， clinical efficacy， inflammatory indicators， and total incidence of adverse reactions between the two groups of children. Result The results showed that the traditional Chinese medicine syndrome score and inflammatory indicators in the combined group were lower than those in the conventional group （P < 0.05）， and the clinical efficacy level distribution was better than that in the conventional group （P < 0.05）. The total effective rate was higher than that in the conventional group （P < 0.05）， and there was no difference in the total incidence of adverse reactions between the two groups （P > 0.05）. Conclusion In the treatment of children with lobar pneumonia （lung spleen deficiency syndrome） caused by Mycoplasma pneumoniae infection， the modified Ginseng Wuweizi decoction has a positive therapeutic effect and good safety， and is worth promoting.

Key words: ginseng schisandra decoction, mycoplasma pneumoniae, lobar pneumonia, lung and spleen qi deficiency syndrome, children, clinical efficacy, inflammatory indicators